F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022

Rhea-AI Summary

F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced a conference call scheduled for March 14, 2022, at 9:00 a.m. EST to discuss its fourth quarter and full-year 2021 financial results and provide a corporate update. Investors can access the call via a live webcast or by phone. F-star is focused on developing innovative immunotherapies for cancer treatment and has several second-generation therapeutics in the clinic, employing its proprietary antibody discovery platform backed by over 500 patents.

Positive

• F-star is advancing four second-generation immuno-oncology therapeutics targeting critical cancer treatment areas.
• The company has an extensive intellectual property portfolio with over 500 granted patents and pending applications.

Negative

• None.

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that the Company will hold a conference call and webcast on March 14, 2022, at 9:00 a.m. EST to review fourth quarter and full-year 2021 financial results and provide a corporate update.

To access the call, participants may join via a live webcast on the Investors and News section of the F-star Therapeutics website, under Events and Presentations. To join by phone, participants may dial the following numbers at least 10 minutes prior to the start of the call:

US/Canada:	1-833-471-0868
International:	1-914-987-7751
United Kingdom:	800 0288438 or 0203 1070289

A replay of the conference call will be available for 90 days from the call and may be accessed in the Investors & News/Events and Presentations section on the F-star Therapeutics website.

About F-star Therapeutics, Inc.

F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy. The Company has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate. F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.

For more information visit our website and follow us on LinkedIn and Twitter.

For further information, please contact:

For investor inquiries
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@fstar.com

John Fraunces
Managing Director
LifeSci Advisors LLC
+1 917 355 2395
jfraunces@lifesciadvisors.com

For media inquiries
Helen Shik
Shik Communications LLC
+1 617-510-4373
helen@shikcommunications.com 

FAQ

What are the details of F-star Therapeutics' upcoming conference call?

F-star Therapeutics will hold a conference call on March 14, 2022, at 9:00 a.m. EST to discuss its fourth quarter and full-year 2021 financial results.

What therapeutic areas is F-star Therapeutics focusing on?

F-star Therapeutics is focused on developing next-generation immunotherapies for cancer, including targets like LAG-3 and CD137.

How can investors access the F-star Therapeutics conference call?

Investors can join the conference call via a live webcast on F-star's website or by phone using designated dial-in numbers.